Evaluation of the RESTART Survival Programme
Launched by JULES BORDET INSTITUTE · Feb 22, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The RESTART Survival Programme is a clinical trial designed to evaluate how satisfied patients are with a support program for those who have been treated for localised breast cancer. Since its start in 2022, this program aims to help patients improve their quality of life and understand their health better after treatment. Researchers will look at how participating in the RESTART programme affects these areas for patients.
To be eligible for this trial, participants need to be at least 18 years old, understand some French, and have signed a consent form to take part. They should also be patients with curable breast cancer at an early stage (stages I to III) and have participated in the RESTART programme. While the trial is not currently recruiting participants, it will gather important insights about the effectiveness of the RESTART programme in supporting breast cancer survivors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age \>= 18 at the time of signing the ICF
- • 2. Minimum understanding of French
- • 3. Signed study informed consent form obtained prior to any study-related procedure.
- • 4. Participation in the RESTART programme
- • 5. Patient with curative breast cancer (AJCC stage I-II-III)
- Exclusion Criteria:
- • -
About Jules Bordet Institute
The Jules Bordet Institute is a prestigious cancer research and treatment center located in Brussels, Belgium, dedicated to advancing oncology through innovative clinical trials and multidisciplinary care. As a leading sponsor of clinical research, the institute focuses on developing novel therapeutic approaches and improving patient outcomes in various cancer types. With a commitment to scientific excellence and collaboration, the Jules Bordet Institute leverages cutting-edge technologies and a robust network of healthcare professionals to foster breakthroughs in cancer treatment and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported